Research Updates

Government announces major prostate cancer screening trial to end needless prostate deaths

Government announces major prostate cancer screening trial to end needless prostate deaths
Research Updates

Pluvicto™ Update

Pluvicto™ Update
Research Updates

Darolutamide with Docetaxel approved for treatment of mHSPC in Scotland

Darolutamide with Docetaxel approved for treatment of mHSPC in Scotland
Fundraising, PCR News

Walk 60 Miles in November for Prostate Cancer

Walk 60 Miles in November for Prostate Cancer
PCR News

PCR submits evidence to the Health and Social Care Committee as part of inquiry into men’s health

PCR submits evidence to the Health and Social Care Committee as part of inquiry into men’s health
All, Fundraising, PCR News

PCR partners with CAC for Prostate Cancer Awareness Month

PCR partners with CAC for Prostate Cancer Awareness Month
All, PCR News

Bayer and Advanced Accelerator Applications (A Novartis Company) sponsor charity Prostate Cancer Research’s new collaborative project supported by IQVIA and backed by over 3,000 patients that aims to unleash the potential of health data

Bayer and Advanced Accelerator Applications (A Novartis Company) sponsor charity Prostate Cancer Research’s new collaborative project supported by IQVIA and backed by over 3,000 patients that aims to unleash the potential of health data
Research Updates

Exploring men’s psychological adjustment to prostate cancer

Exploring men’s psychological adjustment to prostate cancer
Fundraising, PCR News, Supporter Stories

Jeanette Ager Braves the Thames Marathon Swim for Prostate Cancer Research

Jeanette Ager Braves the Thames Marathon Swim for Prostate Cancer Research
All

Prostate Cancer Research statement on the NCRI

Prostate Cancer Research statement on the NCRI
Prostate Cancer Stories

Flossing for the future

Flossing for the future
Research Updates

NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer

NICE recommends darolutamide with androgen deprivation therapy and docetaxel for patients with hormone-sensitive metastatic prostate cancer
Load more
Press enter or esc to cancel